{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.8","upperLimit":"57.8","value":"46.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"description":"ORR assessed by the independent radiological review committee (IRRC) according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received sugemalimab (CS1001) 1200 mg intravenously every 3 weeks (Q3W)","id":"OG000","title":"R/R ENKTL"}],"paramType":"NUMBER","populationDescription":"Two patients were excluded from analysis: one patient was not confirmed as ENKTL by central pathology, and the other patient was identified as having no measurable or evaluable disease at baseline by IRRC.","reportingStatus":"POSTED","timeFrame":"From enrollment to end of follow-up, a median of 29 months","title":"Objective Response Rate (ORR) Assessed by IRRC","type":"PRIMARY","unitOfMeasure":"percentage of Participants"}